Comprehensive Molecular Profiling in Cholangiocarcinoma: A Patient Cohort Analysis
Brazilian Journal of Oncology · 26.06.2026 · 22 (CP)
DOI: 10.1055/s-0046-1825482 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brazilian Journal of Oncology, erschienen am 26.06.2026. Verfasst von Vinícius Lorandi und 6 weiteren Autor:innen.
Abstract (Originalsprache)
All articles of this category (opens in new window) Address for correspondence Vinícius Lorandi (vlorandi@gmail.com)
Introduction
In recent years, understanding of Cholangiocarcinoma (CCA) molecular biology has advanced significantly, revealing a heterogeneous landscape of genomic alterations that can serve as targets for personalized therapies. Identifying these molecular drivers is crucial for patient stratification and the development of tailored therapeutic approaches aimed at improving clinical outcomes. This study aimed to determine the prevalence of clinically relevant actionable genomic alterations in a cohort of cholangiocarcinoma patients tested in a reference laboratory in Brazil.
Methods
Retrospective analysis of all cholangiocarcinoma samples diagnosed between 2020 and 2025 at OC Medicina de Precisão and who had informative genomic profiling results. Molecular characterization was performed using next-generation sequencing (NGS) techniques on tumor samples, covering a panel of genes frequently altered in CCA, including point mutations, indels, gene fusions, and assessment of microsatellite instability (MSI) and tumor mutational burden (TMB).
Results
In total, 217 CCA samples were analyzed, of whom 122 (56.2%) were female patients. Median age at diagnosis was 66 years (25-94 years). The most frequently observed mutations were in TP53 in 29.5% and KRAS in 20.3%. IDH1 mutations were detected in 11.1% of cases (9.0% R132C variant). FGFR2 fusions were found in 8.3% of patients, while FGFR3 fusions were present in 4.1%. BRAF V600E mutation was found in 1.4%, while microsatellite instability (MSI) and tumor mutational burden (TMB) high was rare, observed in less than 1% of cases.
Discussion
This study is the first molecular characterization of advanced CCA in Brazil. corroborating the heterogeneity and the importance of genomic profiling in the clinical practice. Overall, 26% of CCA samples harbor actionable alterations in IDH1, FGFR, BRAF, MSI or TMB. The prevalence of each alteration is comparable to international literature. Publication History Article published online: 26 June 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil Bibliographical Record Vinícius Lorandi, Rodrigo Dienstmann, Breno Jeha, Amanda Muniz Rodrigues, Carolina de Bustamante Fernandes, Gabriel Prolla, Alexandre Jácome. Comprehensive Molecular Profiling in Cholangiocarcinoma: A Patient Cohort Analysis. Brazilian Journal of Oncology 2026; 22. DOI: 10.1055/s-0046-1825482
Zitieren
APA
Lorandi, V., Dienstmann, R., Jeha, B., Rodrigues, A. M., Fernandes, C. D. B., Prolla, G., & Jácome, A. (2026). Comprehensive Molecular Profiling in Cholangiocarcinoma: A Patient Cohort Analysis. Brazilian Journal of Oncology, 22(CP). https://doi.org/10.1055/s-0046-1825482
Vancouver
Lorandi V, Dienstmann R, Jeha B, Rodrigues AM, Fernandes CDB, Prolla G, et al. Comprehensive Molecular Profiling in Cholangiocarcinoma: A Patient Cohort Analysis. Brazilian Journal of Oncology. 2026;22(CP). doi:10.1055/s-0046-1825482
BibTeX
@article{Lorandi2026,
author = {Lorandi, Vinícius and Dienstmann, Rodrigo and Jeha, Breno and Rodrigues, Amanda Muniz and Fernandes, Carolina de Bustamante and Prolla, Gabriel and Jácome, Alexandre},
title = {Comprehensive Molecular Profiling in Cholangiocarcinoma: A Patient Cohort Analysis},
journal = {Brazilian Journal of Oncology},
year = {2026},
volume = {22},
number = {CP},
doi = {10.1055/s-0046-1825482}
}
EUVIMED